FXYD6

Across TCGA pan-cancer cohorts, FXYD6 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated FXYD6 data layer compared with 4 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher FXYD6 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated FXYD6 expression acts as an unfavorable survival marker, although some lineages such as KIRC and UCS show a favorable association.

BLCA, KIRC, and UCS are the cancer types where FXYD6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.436	0.582	<.001	84	view →
KIRC	OS	Median	All	0.718	0.547	<.001	78	view →
UCS	DFS	Median	III,IV	0.524	0.149	.003	70	view →
MESO	OS	Median	IV	0.293	0.789	.002	56	view →
LGG	DFS	Median	All	0.841	0.625	<.001	54	view →
PAAD	DFS	Median	All	0.372	0.199	.001	49	view →
LIHC	OS	Tertile	All	0.855	0.711	<.001	48	view →
UCEC	OS	Quartile	All	0.611	0.829	<.001	44	view →
LAML	DFS	Quartile	All	0.267	0.580	.004	36	view →
UVM	DFS	Median	All	0.327	0.637	.002	33	view →
THCA	DFS	Quartile	IV	0.984	0.489	<.001	29	view →
GBM	DFS	Median	All	0.375	0.192	.006	21	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

FXYD6–BLCA (DFS)

Open the BLCA breakdown →